Jacques Mizrahi has been trained in both France (Paris, INSERM U36) and Canada (University of Sherbrooke, Faculty of Sciences and Medical School) in Physiology and Pharmacology. Jacques has then spent over 20 years in Research and Development in pharmaceutical companies GSK (France), Eli Lilly (USA) and more recently at Roche (Switzerland) as Global Therapy Head in Cardiovascular and Metabolic Diseases. Jacques has also led the Clinical Research and Exploratory Medicine Department for Translational Medicine bridging the preclinical discovery efforts to the clinical proof of concept of several innovative programs.
From 2014 and on, Jacques is a partner of Venture Capital organization, Academic institutions as INSERM Transfert (Paris.France) and member of the board of several biotech companies in Europe.
Dr. Wiley earned his PhD in chemistry from University of Utah and finished postdoctoral training at Columbia University. He is a well-recognized drug discovery leader with 30 years of experience in the pharmaceutical industry. Most recently, he was Research Fellow at Eli Lilly and company. He has been a successful scientific leader to deliver multiple clinical candidates across diverse therapeutic areas. His expertise spans a wide range of target families, biochemical pathways, chemotypes and mechanisms of action. In addition, Dr. Wiley is also appreciated for his passion of sharing, coaching and mentoring people in the industry across diverse disciplines, cultures and geographies.